What is Praeventix?
Praeventix, founded by Dr. Douglas Pippin based on research conducted at Temple University, is a biopharmaceutical company focused on pioneering neuromodulatory therapies. The company's lead candidate, PRA-523, is being developed as a potential first-in-class treatment for pruritus and inflammatory bowel disease (IBD). Beyond these indications, Praeventix is also exploring 5-HT7 modulators for the potential treatment of cocaine use disorder (CUD), positioning itself at the forefront of addressing unmet medical needs in both chronic conditions and substance use disorders.
How much funding has Praeventix raised?
Praeventix has raised a total of $3.1M across 2 funding rounds:
Debt
$69K
Private Equity
$3M
Debt (2021): $69K with participation from PPP
Private Equity (2026): $3M, investors not publicly disclosed
Key Investors in Praeventix
PPP
Public-Private Partnership
What's next for Praeventix?
The recent major strategic investment signals a pivotal growth phase for Praeventix, likely enabling the acceleration of its pre-clinical development pipeline and the advancement of PRA-523 towards clinical trials. This capital infusion is expected to bolster research efforts, expand the scientific team, and potentially forge strategic partnerships to further validate and commercialize its innovative therapeutic platforms. The company's focus on both pruritus and CUD indicates a diversified approach to leveraging its neuromodulatory expertise.
See full Praeventix company page
